Read our analysis of key stories from ESMO 2017…

FirstWord Pharma PLUS subscribers can read our analysis of key presentations made at this weekend's European Society of Medical Oncology (ESMO) congress in Madrid, Spain. We will update this page over the course of the week.

Latest posts

Physician Views: Practice-changing data in lung cancer at ESMO? – we're asking oncologists

ViewPoints: ESMO 2017 – Keytruda breaks away from the pack in bladder cancer

ViewPoints: ESMO 2017 – Study author proclaims Opdivo/Yervoy the new standard of care in first-line renal cancer, but don't write the competition off just yet

ViewPoints: ESMO 2017 – A face in the crowd? Eli Lilly's abemaciclib seen to enhance class benefit of CDK4/6 inhibitors

ESMO Spotlight: AstraZeneca delivers compelling riposte to MYSTIC setback with PACIFIC, FLAURA data

ESMO Spotlight: Despite more positive data, Merck & Co. unable to fully shrug off chemo/combo uncertainties

ViewPoints: ESMO 2017 – Merck & Co. continues its march towards a maiden PD-1 approval in gastric cancer

ViewPoints: ESMO 2017 – Jury still out on Roche's taselisib

 

Preview articles

ViewPoints: ESMO 2017 – Roche set to polish its already impressive ALEX data

ViewPoints: ESMO 2017 – where is the bar set for AstraZeneca's FLAURA trial?

ViewPoints: ESMO 2017 – expectations high for AstraZeneca's PACIFIC data

ViewPoints: ESMO 2017 – will updated Keynote-021 data nudge Merck & Co.'s chemo-combo further into the treatment paradigm for NSCLC?

ViewPoints: ESMO 2017 - more of the same at Incyte makes for a rousing success

ESMO 2017 Preview – What to watch

To read more Spotlight On articles, click here.